2013-03-07 08:09:08 -

BIOTIE THERAPIES CORP.    STOCK EXCHANGE RELEASE 7 March 2013 at 9.00 a.m.

Biotie's Annual Financial Report and Corporate Governance Statement 2012
published

Biotie Therapies Corp.' s  Annual financial report for the financial period
ended 31 December 2012 as well as Corporate Governance Statement 2012 have been
published.

The documents are attached in pdf format in this release. Both documents are
also available at Biotie's website www.biotie.com in English and Finnish
language.

Turku, 7 March 2013

Biotie Therapies Corp.

Timo Veromaa
President and CEO

For further information, please contact:

Virve Nurmi, Biotie Therapies Corp.
tel. +358 2 274 8900
e-mail: virve.nurmi@biotie.com

DISTRIBUTION
NASDAQ OMX Helsinki Ltd
Main Media
www.biotie.com

About Biotie

Biotie is a specialized drug development company focused on the development of
drugs for neurodegenerative and psychiatric disorders (e.g. Parkinson's disease,
Alzheimer's disease and other cognitive disorders, alcohol   and drug dependence
(addiction) and post-traumatic stress disorder), and inflammatory and fibrotic
liver disease. The company has a strong and balanced development portfolio with
several innovative small molecule and biological drug candidates at different
stages of clinical development. Biotie's products address diseases with high
unmet medical need and significant market potential.

Biotie's most advanced product, Selincro(TM) (nalmefene), licensed to Lundbeck
A/S, has on 28 February 2013 received European marketing authorization for the
reduction of alcohol consumption in adult patients with alcohol dependence who
have a high level of alcohol consumption. In addition, Biotie has a strategic
collaboration with UCB Pharma S.A. covering tozadenant which is transitioning
into Phase 3 development,

Biotie shares are listed on NASDAQ OMX Helsinki Ltd.


Biotie_Financial statements 2012: 
 hugin.info/132030/R/1683596/551050.pdf

Biotie_Corporate Governance Statement 2012: 
 hugin.info/132030/R/1683596/551051.pdf



This announcement is distributed by Thomson Reuters on behalf of 
Thomson Reuters clients. The owner of this announcement warrants that: 
(i) the releases contained herein are protected by copyright and 
    other applicable laws; and 
(ii) they are solely responsible for the content, accuracy and 
     originality of the information contained therein. 
    
Source: Biotie Therapies Oyj via Thomson Reuters ONE
[HUG#1683596]